A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D / 부인종양
Journal of Gynecologic Oncology
;
: e112-2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-764560
ABSTRACT
BACKGROUND:
A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in treating this cancer can increase progression-free survival (PFS) with minimal effects on safety.METHODS:
During treatment, serial biopsies will be performed on pre-treatment, at interval debulking surgery and progression to identify immune biomarkers and changes in the tumor microenvironment. Patients with histologically confirmed stage IIIC/IV epithelial ovarian cancer are offered durvalumab, tremelimumab plus chemotherapy for neoadjuvant chemotherapy and durvalumab plus chemotherapy for adjuvant chemotherapy. Twenty-four patients will be included from four Korean institutions within 1 year. The primary endpoint is a 12-month PFS rate. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT03899610
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Ováricas
/
Biopsia
/
Biomarcadores
/
Quimioterapia Adyuvante
/
Supervivencia sin Enfermedad
/
Quimioterapia
/
Microambiente Tumoral
/
Inmunoterapia
/
Corea (Geográfico)
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Journal of Gynecologic Oncology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS